Maravai LifeSciences (MRVI) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $46.9–$47 million, exceeding guidance but down 27% year-over-year due to lower CleanCap sales and research demand; base business revenue grew over $4 million sequentially from Q4 2024.

• Net loss widened to $52.9 million from $22.7 million in Q1 2024, driven by a $12.4 million goodwill impairment and lower gross profit.

• Adjusted EBITDA was negative $10.5–$11 million, compared to positive $7.8–$8 million in Q1 2024.

• The company is executing a return-to-growth strategy, focusing on innovation, portfolio expansion, and integration of recent acquisitions.

• Two acquisitions completed: Molecular Assemblies and Officinae Bio, expanding technology and product offerings.

Financial highlights

• Gross margin declined to 16.5% from 40.3% year-over-year, impacted by higher fixed facility costs and depreciation.

• Basic and diluted EPS was a loss of $0.21 per share; adjusted EPS was a loss of $0.08 per share.

• Cash and cash equivalents were $285 million at quarter-end, with $298 million in long-term debt.

• Cash used in operations was $9–$9.4 million; net investing outflows were $23–$23.1 million, mainly for acquisitions and CapEx.

• Operating expenses increased 15.6% to $96 million, mainly due to goodwill impairment.

Outlook and guidance

• Full-year 2025 revenue guidance reaffirmed at $185–$205 million, excluding potential high-volume CleanCap orders and future acquisitions.

• Q2 revenue expected between $45–$50 million; first-half 2025 at about $95 million.

• No high-volume CleanCap orders expected for the remainder of 2025, which will significantly decrease revenue, profitability, and cash flows.

• CapEx for 2025 projected at $15–$20 million, with $10 million for enzyme manufacturing expansion.

• Cash on hand and access to credit facilities deemed sufficient for the next 12 months and beyond.